advertisement

WGC-2021

11.16 Vehicles, delivery systems, pharmacokinetics, formulation (119)

Showing records 1 to 25

Display all abstracts in classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation

Search within classification 11.16 Vehicles, delivery systems, pharmacokinetics, formulation
86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Esteban-Pérez S
Pharmaceutics 2020; 12:
86597 Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016
Chamard C
Acta Ophthalmologica 2020; 0:
86753 Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases
Durgun ME
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 323-341
86722 Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits
Roy Chowdhury U
PLoS ONE 2020; 15: e0231841
86339 Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy
Li T
Drug Delivery 2020; 27: 410-421
86685 Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Fathalla D
Drug Development and Industrial Pharmacy 2020; 46: 806-813
86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
López ES
Current Pharmaceutical Design 2020; 26: 1235-1250
86651 Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery
Sun J
Journal of materials chemistry. B 2017; 5: 6400-6411
86221 Tear Meniscus Imaging by Anterior Segment-Optical Coherence Tomography in Medically Controlled Glaucoma
Agnifili L
Journal of Glaucoma 2020; 29: 374-380
86844 Incorporation of ion exchange functionalized-montmorillonite into solid lipid nanoparticles with low irritation enhances drug bioavailability for glaucoma treatment
Liu S
Drug Delivery 2020; 27: 652-661
86715 Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops
Inoue D
Cutaneous and Ocular Toxicology 2020; 39: 158-164
86432 Reduction of intraocular pressure using timolol orally dissolving strips in the treatment of induced primary open-angle glaucoma in rabbits
El-Feky YA
Journal of Pharmacy and Pharmacology 2020; 72: 682-698
86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Pakuliene G
Journal of Ophthalmology 2020; 2020: 7345687
86650 Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma
Liao YT
Journal of materials chemistry. B 2017; 5: 7008-7013
86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Erichev VP
Vestnik Oftalmologii 2019; 135: 117-123
86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Dorofeev DA
Vestnik Oftalmologii 2019; 135: 52-59
86724 Progress on ocular siRNA gene-silencing therapy and drug delivery systems
Jiang J
Fundamental and Clinical Pharmacology 2020; 0:
86433 Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy
Luo LJ
Biomaterials 2020; 243: 119961
86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Hedengran A
British Journal of Ophthalmology 2020; 0:
86199 Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges
Machado ALL
Current Pharmaceutical Design 2020; 26: 1235-1250
86078 The effect of preservative-free treatment of primary open-angle glaucoma on the state of ocular surface in combination therapy (intermediate results)
Tur EV
Vestnik Oftalmologii 2019; 135: 52-59
86080 Continuous anti-glaucoma drug therapy as a risk factor of dry eye
Petrov SY
Vestnik Oftalmologii 2019; 135: 117-123
86156 Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Steensberg AT
British Journal of Ophthalmology 2020; 0:
86592 Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents
Andrés-Guerrero V
Pharmaceutics 2020; 12:
86682 Factors Predetermining Increased Aqueous Humour Flare in Long-Term Glaucoma Treatment
Kuzmiene L
Journal of Ophthalmology 2020; 2020: 7345687

Issue 21-2

Change Issue


advertisement

WGC-2021